Psychedelic medicines may represent a new frontier for end-of-life care, as well as psychiatric treatment. While these substances including LSD, MDMA, psilocybin and ketamine, among others remain illegal, grass roots support for decriminalization or medical use is growing. Meanwhile, venture capitalists and other investors are spending billions to get on the ground floor of what could become a new health care industry.
Much of the research and discussion on medical use of psychedelics has focused on care at the end of life. Interest in the potential medical benefits of these substances became widespread during the 1960s, but research all but stopped after they were criminalized through federal legislation in 1970. The first inklings of a resurgence began in the late 1990s, and momentum has picked up during the last decade.
The evidence is just so compelling, and we have very little in terms of tools in our medical bag to be able to help people who are suffering from existential distress, anxiety and depression related to a serious illness diagnosis, Shoshana Ungerleider, M.D., internist at Crossover Health in San Francisco, founder of the organization End Well,said. We want people to be able to live fully until they die. If psychedelics given in a controlled therapeutic environment with trained clinicians who can help them do that, then these medicines should be more widely available.
End Well recently produced a conference on the subject of psychedelic medicine for dying patients.
The body of scientific literature on psychedelics for dying patients continues to advance. Johns Hopkins Medicine in 2019 established a Center for Psychedelic and Consciousness Research backed by $17 million in grants.
Researchers have identified a number of clinical benefits, including reduction of anxiety, depression and improved acceptance of mortality, according to a 2019 literature review in the journal Current Oncology. The paper cited studies indicating that the most commonly used psychedelic drugs have no tissue toxicity, do not interfere with liver function, have few interactions with other medications and carry no long-term physical effects. Common side effects tend to be short in duration, such as nausea and vomiting or disruption of visual or spatial orientation.
Patients who use psychedelic medicines often report what researchers commonly describe as a mystical experience, involving a feeling of unity, sacredness, deeply-felt positive mood, transcendence of space and time, and other effects that study participants found difficult to verbalize, according to the Current Oncology paper.
This can be transformative for people with anyone who is wracked with trauma, grief, loss or extreme states of suffering, Sunil Aggarwal, M.D., co-founder, co-director and practitioner at the Advanced Integrative Medical Science (AIMS) Institute in Seattle, told Hospice News. Theres also evidence that these substances can also reduce physical pain.
Aggarwal is a board-certified hospice and palliative care physician and a past chair of the American Academy of Hospice and Palliative Medicine (AAHPM).
All psychedelics are illegal at the federal level and in most states. Oregon in 2020 became the first in the union to remove criminal penalties for all illegal drugs and is now in the process of establishing the nations first state-licensed psilocybin-assisted therapy system.
More action has been happening at the local level, with communities such as Washington, D.C., Denver, Ann Arbor, Mich., three Massachusetts cities, and Santa Cruz and Oakland in California voting to decriminalize some psychedelics and permit medical use. Some of these regions are now considering statewide decriminalization.
Connecticut and Texas each have laws on the books that created work groups to study the medical use of psilocybin, MDMA and ketamine. Legislatures in Hawaii, Iowa, Maine, Missouri, Vermont and New York state are currently mulling decriminalization or medical use bills.
In late July, Rep. Alexandria Ocasio-Cortez (D-N.Y.) reintroduced an amendment to remove federal barriers to research the therapeutic potential of psychedelic substances. The U.S. House of Representatives quickly shot down the legislation, though it garnered more support this round than the previous time it was introduced.
We quite a few years off from having enough trained therapists and a policy pathway for which these can be made more widely available in a controlled therapeutic setting, Ungerleider said. Theres just so much interest right now among patients and among family members to learn more about this. All health care professionals need to have an understanding of where were at with psychedelics.
Interest in psychedelics has transcended the research space and entered the business world. The familiar adage, follow the money, frequently provides good indicators of which way the wind is blowing.
The psychedelics industry is expected to bring in more than $6.85 billion by 2027, Forbes reported. Many of these investors are seeking to reproduce the lucrative results of the cannabis industry that emerged in the wake of legalization among a number of states. A recent report indicated that 36 states and four territories allow use of medical cannabis products, according to the National Conference of State Legislatures.
The largest investors in psychedelics include the venture capital firms Conscious Fund, Explorer Equity Group and Pala Santo. Earlier this year, Florida-based cannabis and psychedelics attorney Dustin Robinson co-founded Iter Investments, a new venture capital group focused on that sector.
A United Kingdom-based psychedelics-focused pharmaceutical company, Compass Pathways (NASDAQ: CMPS), went public in Sept. 2020 and is now worth an estimated $1.2 billion.
Theres a unique opportunity to be able to go ahead and develop and commercialize [psychedelics] to a much larger patient population, health care investor and venture capitalist Andrew Lee told Hospice News. Itll be interesting to see how natural pharmaceuticals might work. Theres the nonprofit, sacred path, the pharma path and the botanical drug sort of path. The most important thing is that this is another tool in the toolbox for treating a number of conditions.
Originally posted here:
Psychedelics Could Be New Frontier in End-of-Life Care - Hospice News
- Psychedelic Water CEO Pankaj Gogia Talks About The Future Of Psychedelics - Exclusive - Health Digest - August 2nd, 2022
- Biden Administration Says Task Force Is Needed to Advance Psychedelics Research - Green Entrepreneur - August 2nd, 2022
- Legalizing the trip: One 'shroom advocate's playbook - POLITICO - August 2nd, 2022
- 'The result was a rebirth. I finally got where I wanted to go': Celebs who have tried psychedelics - The Daily Post-Athenian - August 2nd, 2022
- Texas' first Ceremonial Psychedelic Treatment Center WITHIN opens in Austin - PR Web - August 2nd, 2022
- Postdoctoral Research Fellow in Psychedelics, Neurodevelopment and Electrophysiology job with UNIVERSITY OF SYDNEY | 303322 - Times Higher Education - August 2nd, 2022
- Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca's Effects on Trauma - Business Wire - August 2nd, 2022
- Good Trip? How Psychiatrists Got Serious About Using Psychedelics to Treat Mental Health - Robb Report - July 25th, 2022
- The hope and hype of psychedelic therapy - ABC News - July 25th, 2022
- Microdosing Psilocybin Mushrooms May Improve Mental Health and Mood - Healthline - July 25th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of July 18 - The Dales Report - July 25th, 2022
- Psyched Up: The race to make psychedelic drugs part of mainstream medicine - ABC News - July 25th, 2022
- Keeping the Hippie Dream Alive - The New York Times - July 25th, 2022
- DEA Sued Over Delays To Open Records For Psychedelics And Cannabis - Benzinga - Benzinga - July 25th, 2022
- Trade to Black Podcast: the Senate Vs the Cannabis Administration Opportunity Act - The Dales Report - July 25th, 2022
- Otago academic and comedian takes on the science of getting high - Stuff - July 25th, 2022
- Can mad honey get you high? A bee expert reveals the answer - Inverse - July 25th, 2022
- The promise of psychedelics - Investors' Chronicle - Investors Chronicle - July 14th, 2022
- House Moves to Expand Psychedelic Therapy Research - The Intercept - July 14th, 2022
- Ann Shulgin, pioneer of psychedelics in therapy, dies at 91 - ABC News - July 14th, 2022
- Doctors Urge Access to Psychedelic Therapies in New Mexico - TIME - July 14th, 2022
- States That Have Made Advancements Toward Legalizing Psychedelics - StreetInsider.com - July 14th, 2022
- Canada: 100+ Healthcare Professionals Protest Psilocybin Access Ban For Psychedelics-Assisted Therapy Training - Benzinga - July 14th, 2022
- Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre - Marketscreener.com - July 14th, 2022
- Psychedelics gave me the courage to take charge of my romantic life - Mic - July 7th, 2022
- Goodbye Weed and Acid, Hello Magic Mushrooms - Psychedelic Spotlight - July 7th, 2022
- Meet the Married Couple Trailblazing the Development of Psychedelic Therapies - PR Newswire - July 7th, 2022
- Berkeley's psychedelic rebbe is ready for the first Jewish cannabis retreat - The Jewish News of Northern California - July 7th, 2022
- CaaMTech Collaborates With the Alexander Shulgin Research Institute to Study Shulgin Compounds - Newswire - July 7th, 2022
- Origin Therapeutics adds Clairvoyant Therapeutics to its Portfolio - GlobeNewswire - July 7th, 2022
- Psychedelic-Assisted Therapy & Medicine - Psychedelics.com - July 4th, 2022
- Can microdosing psychedelics improve your mental health? Here's what the science says - ABC News - July 4th, 2022
- Inside Vision Treks: The Mind Armys Psychedelic Retreat Takes Strangers Into The Desert - Forbes - July 4th, 2022
- GOP Congressman's Amendment Would Direct Military To Study Psilocybin And MDMA Benefits For Service Members - Marijuana Moment - July 4th, 2022
- Magic mushrooms: BC production facility one of a handful licensed to grow - CTV News - July 4th, 2022
- 3 Paranormal Experiences That Have Caught The Attention Of Mental Health Researchers - Forbes - July 4th, 2022
- VA Studying Psychedelics As Mental Health Treatment For Veterans - Forbes - June 29th, 2022
- 10 Psychedelics CEOs To Pay Attention To In 2022 - Yahoo Finance - June 29th, 2022
- Secret ancient Andean passageways may have been used in rituals involving psychedelics - Livescience.com - June 29th, 2022
- How psychedelics act on the brain to relieve depression - Daily Maverick - June 29th, 2022
- Magic mushrooms are all the rage. But are they Jewish? - The Guardian - June 29th, 2022
- Treating Stress with Wearable Technology - Psychedelic Spotlight - June 29th, 2022
- Numinus Applies for International Patent Filing of Psychedelics Production Process - PR Newswire - June 29th, 2022
- This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More! - Psychedelic Spotlight - June 29th, 2022
- Is there a future for psychedelic treatment in Saudi Arabia? - Arab News - June 29th, 2022
- Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA - Marketscreener.com - June 29th, 2022
- Braxia Scientific CEO to Deliver Keynote Address at HC Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and... - June 29th, 2022
- Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review - Cureus - June 29th, 2022
- How an NHL Enforcer Broke His Body and Turned to Psychedelics to Heal His Brain - Rolling Stone - June 22nd, 2022
- The top psychedelic drug developers leading the market - Labiotech.eu - June 22nd, 2022
- Numinus Applies for International Patent Filing of Psychedelics Production Process - Yahoo Finance - June 22nd, 2022
- Two psychedelic-related initiatives may be on the 2022 Colorado ballot - Denver 7 Colorado News - June 22nd, 2022
- Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights - Business Wire - June 22nd, 2022
- SPOTLIGHT IN FOCUS - The Rise of Psychedelic Therapy - Psychedelic Spotlight - June 22nd, 2022
- Rapper Vic Mensa has a more badass fitness routine than you thanks to martial arts, psychedelics and meditation - British GQ - June 22nd, 2022
- What is Ego Death And How Does it Work? - Benzinga - Benzinga - June 22nd, 2022
- Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD - Neurology Live - June 11th, 2022
- Stephen Asma: My father's experience with morphine in hospice showed me the healing joy of altered states - Chicago Tribune - June 11th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 30 - The Dales Report - June 5th, 2022
- Psychedelic Wellness: 5 Magical Benefits of Magic Mushrooms - Longevity LIVE - Longevity LIVE - June 5th, 2022
- 'Magic mushrooms drug could help depression sufferers in the years to come' - Irish Mirror - June 5th, 2022
- Tripping over the potential of psychedelics for autism | Spectrum - Spectrum - June 3rd, 2022
- Can you take the trip out of psychedelics and still treat depression? - New Scientist - June 3rd, 2022
- We spark curiosity: how the psychedelics industry is taking on Davos - The Guardian - June 3rd, 2022
- Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy - Business Wire - June 3rd, 2022
- Ketamine can treat depression but teletherapy could make it accessible - Inverse - June 3rd, 2022
- 2022-06-01 | PINL:EHVVF | Press Release | ehave Inc - Stockhouse - June 3rd, 2022
- VIDEO: The Weekly Weed Report (05-31-22) - Investing Daily - Investing Daily - June 3rd, 2022
- Psychedelics Companies in Oregon Will Have to Grapple With 280E - Business Insider - May 21st, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 16 - The Dales Report - May 21st, 2022
- Psychedelics and Mindfulness: The Future of Mental Health? | Microdose - Microdose Psychedelic Insights - May 21st, 2022
- CATALYST Summit: 3 Psychedelic Speakers to Catch This Weekend - Psychedelic Spotlight - May 21st, 2022
- 'I took ketamine to treat my severe depression' - iNews - May 21st, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of May 9 - The Dales Report - May 15th, 2022
- Psychedelic Patents are Broken Because the Patent System Is Broken - VICE - May 15th, 2022
- Magic mushrooms are on WeHos mind - WEHOville - May 15th, 2022
- Behind the Scenes on the First Study To Compare the Effects of LSD and Psilocybin - Technology Networks - May 15th, 2022
- Revitalist's Strategic Initiatives Continue to Exceed Expectations for Execution Giving Company Record High Revenues Since Opening in 2018. - Business... - May 15th, 2022
- MDMA as medicine: Stemming the tide of veteran suicides in Western North Carolina - Smoky Mountain News - May 15th, 2022
- Cybin's CYB0004 Shows Positive Preclinical Results Over ... - May 3rd, 2022